New eye implant could slow vision loss from dry AMD
NCT ID NCT07668804
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a biodegradable eye implant called TO-O-1007 for geographic atrophy, a form of advanced dry age-related macular degeneration that causes blind spots. The implant slowly releases medication over 6 months to slow disease progression. About 31 adults aged 50 and older will receive either a low-dose, high-dose, or sham injection to evaluate safety and early effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TO-O-1007 implant
- What this could lead to
- If successful, this could lead to a treatment that slows vision loss from geographic atrophy with fewer injections.
- What could go wrong
- This is an early phase trial with only 31 people, so safety and effectiveness are not yet proven. The implant may not slow disease progression or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GEOGRAPHIC ATROPHY DUE TO AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Launceston Eye Doctors
RECRUITINGLaunceston, Tasmania (tas), 7250, Australia
-
Retina & Eye Consultants
RECRUITINGHurstville, New South Wales (nsw), 2220, Australia
-
Sydney Retina Clinic & Day Surgery
RECRUITINGSydney, New South Wales (nsw), 2000, Australia